Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
The Oncologist · 2024
DOI: 10.1093/oncolo/oyad201 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Nicoletta Colombo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Department, European Institute of Oncology IRCCS, Milan, Italy. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Hypertension, Hypothyroidism, Musculoskeletal Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endometrial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression following prior platinum-based therapy, in Study-309/KEYNOTE-775. The safety profile of the combination was generally consistent with that of each monotherapy drug and of the combination in patients with endometrial cancer and other solid tumors. Given the medical complexity of patients with aEC, this paper aims to characterize key adverse reactions (ARs) of the combination treatment and review management strategies, providing a guide for AR management to maximize anticancer benefits and minimize treatment discontinuation. Materials and Methods In Study-309/KEYNOTE-775, patients received lenvatinib (20 mg orally once daily) plus pembrolizumab (200 mg intravenously every 3 weeks) or chemotherapy (doxorubicin or paclitaxel). The incidence and median time to the first onset of ARs, dose modifications, and concomitant medications are described. Key ARs characterized include hypothyroidism, hypertension, fatigue, diarrhea, musculoskeletal disorders, nausea, decreased appetite, vomiting, stomatitis, weight decreased, proteinuria, and palmar-plantar erythrodysesthesia syndrome.
Results
As expected, the most common any-grade key ARs included: hypothyroidism, hypertension, fatigue, diarrhea, and musculoskeletal disorders. Grades 3-4 key ARs with incidence ≥10% included: hypertension, fatigue, and weight decreased. Key ARs first occurred within approximately 3 months of treatment initiation. AR management strategies consistent with the prescribing information and the study protocol are discussed.
Conclusion
Successful AR management strategies for lenvatinib plus pembrolizumab include education of the patient and entire treatment team, preventative measures and close monitoring, and judicious use of dose modifications and concomitant medications. Clinicaltrials.gov ID NCT03517449
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gynecologic Oncology Department, European Institute of Oncology IRCCS, Milan, Italy.
- Department of Medicine and Surgery, University of Milan-Bicocca, Italy.
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, Italy.
- HonorHealth Research Institute, University of Arizona, Creighton University, Phoenix, AZ, USA.
- Division of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, FL, USA.
- Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.
ORCID-Profile: Nicoletta Colombo
Förderung
- NCI NIH HHS
Zitieren
APA
Colombo, N., Lorusso, D., Monk, B. J., Slomovitz, B., Hasegawa, K., Nogueira-Rodrigues, A., Zale, M., Okpara, C. E., Barresi, G., McKenzie, J., & Makker, V. (2024). Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. The Oncologist. https://doi.org/10.1093/oncolo/oyad201
Vancouver
Colombo N, Lorusso D, Monk BJ, Slomovitz B, Hasegawa K, Nogueira-Rodrigues A, et al. Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. The Oncologist. 2024. doi:10.1093/oncolo/oyad201
BibTeX
@article{Colombo2024,
author = {Colombo, Nicoletta and Lorusso, Domenica and Monk, Bradley J and Slomovitz, Brian and Hasegawa, Kosei and Nogueira-Rodrigues, Angélica and Zale, Melissa and Okpara, Chinyere E and Barresi, Gianmaria and McKenzie, Jodi and Makker, Vicky},
title = {Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyad201}
}
EUVIMED